SCHEMBL864405

SCHEMBL864405

COCCNc1nc2c(Cl)cccc2cc1C(C)Nc1ncnc2[nH]cnc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 8/20 0.48
KDM4E B2RXH2 3/20 0.46
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KRAS P01116 2/20 0.36
EGFR P00533 1/20 0.36
SOS1 Q07889 1/20 0.36
KMT2A Q03164 2/20 0.35
LDHA P00338 1/20 0.35
PIK3CG P48736 3/20 0.35
PIK3CA P42336 2/20 0.35
PIK3CB P42338 2/20 0.35
ABCB11 O95342 1/20 0.35
TBXA2R P21731 1/20 0.35
PIK3R1 P27986 1/20 0.35
HTR2A P28223 1/20 0.35
PDE3A Q14432 1/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL864404 1.00 PIK3CD (0.48) PIK3CDKDM4ELMNAHTTALDH1A1
SCHEMBL864078 0.95 PIK3CD (0.47) PIK3CDKDM4ELMNAHTTSMN1; SMN2
SCHEMBL864077 0.95 PIK3CD (0.47) PIK3CDKDM4ELMNAHTTSMN1; SMN2
SCHEMBL863729 0.91 PIK3CD (0.47) PIK3CDKDM4ELMNAHTTALDH1A1
SCHEMBL863730 0.91 PIK3CD (0.47) PIK3CDKDM4ELMNAHTTALDH1A1
SCHEMBL864804 0.89 PIK3CD (0.49) PIK3CDKDM4EKRASEGFRSOS1
SCHEMBL864803 0.89 PIK3CD (0.49) PIK3CDKDM4EKRASEGFRSOS1
SCHEMBL864038 0.88 PIK3CD (0.49) PIK3CDKDM4EKRASEGFRSOS1
SCHEMBL865114 0.88 PIK3CD (0.49) PIK3CDKDM4EKRASEGFRSOS1
SCHEMBL863661 0.88 PIK3CD (0.48) PIK3CDKDM4EKRASEGFRSOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2396315-B1 QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-08-31 EP disclosed
US-8513284-B2 Fused pyridine and pyrazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2013-08-20 US disclosed
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors PDPK1, PDXK, PIK3CA PIK3CD 14/4885KDM4E 2074/4885LMNA 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.